By Peter A. McCullough, MD, MPH
I appeared on American Sunrise (10/18/23) with Dr. Gina Loudon to let America know I am not recommending COVID-19 XBB.1.5 Boosters, influenza, or respiratory syncytial virus vaccines for healthy adults or children. None of these vaccines are compelling and conditions are easily treatable. The EUA COVID-19 injections have been determined to be unsafe for human use by the World Council for Health and the Association of American Physicians and Surgeons.
None of these vaccines have compelling efficacy. For example, the RENOIR Trial in 34,284 adults tested the unadjuvanted RSVpreF vaccine at a dose of 120 μg (containing 60 μg each of RSV A and RSV B antigens) (17,215 participants) versus placebo (17,069 participants). RSV-associated lower respiratory tract illness with at least two signs or symptoms occurred in 11 participants in the vaccine group and 33 participants in the placebo group, (vaccine efficacy, 66.7%; 96.66% confidence interval [CI], 28.8 to 85.8); 2 cases and 14 cases with least three signs or symptoms (vaccine efficacy, 85.7%; 96.66% CI, 32.0 to 98.7). RSV-associated acute respiratory illness occurred in 22 participants in the vaccine group and 58 participants in the placebo group, vaccine efficacy, 62.1%; 95% CI, 37.1 to 77.9). There were no hospitalizations or deaths mentioned in either group. Because data are sparse, we must rely on the lower limit of the confidence interval for treatment effect, which is unacceptable being far below 50% for all outcomes.
RSV, like influenza and COVID-19 are easily treatable infections at home. As you can see RSV is very rare with <1% of adults contracting the virus. Vaccinating the entire adult population is an excessive use of a poorly effective new product. For healthy persons, it is perfectly reasonable to skip fall vaccines and seek early treatment in the rare circumstance that one of these viral infections is contracted.
Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Share this post